Participated with a £300K ticket in Cumulus Neuroscience’s £3.25M round for at-home EEG technology for clinical trials, led by WhiteRock Capital Partners.
Cumulus Neuroscience is developing faster, more effective tools to help partners solve healthcare challenges in neurodegeneration and psychiatry
Cumulus Neuroscience is developing faster, more effective tools to help partners solve healthcare challenges in neurodegeneration and psychiatry. They have created a next-generation integrated physiological and digital biomarker platform that provides critical data for accelerating CNS drug delivery.